Starting where poor liver reserve stands between a person and potentially curative treatment. Looking towards a wider horizon of liver health.
Explore our focus
THE UNMET NEED
Liver function can determine which treatments are available. Apterna starts with a defined patient group: people with liver cancer whose poor liver reserve prevents potentially curative surgery.
That focused beginning provides a clinical rationale for exploring functional restoration across a broader liver disease continuum.
OUR AREAS OF FOCUS
Some patients have tumours that may be technically removable, yet too little liver reserve to tolerate surgery. REGEN001 is being developed with the ambition of improving that reserve and expanding treatment possibilities.
See the development programmeA CLINICAL PERSPECTIVE
The functional capacity of the liver is an important part of treatment planning.
Our initial research focuses on a setting where functional improvement could change the options available.
Clinical benefit and future applications must be established through the development process.
Apterna’s programmes are investigational. This information is not medical advice; treatment decisions belong with a qualified clinical team.
CONTINUE EXPLORING
A CLEARER UNDERSTANDING
The initial research focus is liver cancer patients whose poor liver reserve limits access to potentially curative surgery. Apterna aims to investigate whether restoring liver function could broaden treatment possibilities.
Cirrhosis, transplant avoidance and metabolic liver disease are future areas of interest. They represent research ambitions rather than demonstrated treatment outcomes or separate clinical-stage programmes.
